With a new transdermal patch product—methylphenidate (for treatment of ADHD)—, Noven Pharmaceutical’s transdermal development continues to be revolutionary. However, to accommodate its expanding high quality product lines, the company had to increase the efficiency by revolutionizing the equipment on its production floor, which was home to two reliable coating lines.
Will Jackson, technical manager, outlines the key challenges that Noven’s production team faced with its existing coating lines. “One was the lack of commercially available replacement parts for the equipment.”
A Change of Plans
Planning to replace the two coating lines with new equipment, Noven’s executive team met with Maxcess while visiting Packexpo [Chicago 2004] to discuss possible solutions. Noven asked Maxcess to visit its Miami operation with the goal of helping in the decision making process.
But when Maxcess’ local District Manager examined Noven’s existing lines he soon discovered that significant gains in production capacity could be achieved by rethinking the existing process line and integrating new equipment.
To achieve its production expectations of reduced downtime and waste in a cost-effective manner, Noven decided to add a new 30-ft. coating line in addition to upgrading its existing lines, utilizing solutions from all three Maxcess brands: MAGPOWR, Fife, and Tidland.
Retrofit Benefits Performance
The project began with the two existing coating lines receiving complete upgrades to take advantage of newer technology. The existing MAGPOWR tension control system was updated to MAGPOWR’s Versatec and Cygnus systems and TS series load cells. All controls then were integrated into a DCS (distributed controls system) with touchscreen controls.
All Fife pneumohydraulic guides were updated to Fife electromechanical models, controlled with a CDP-01 web guide controller and integrated into the DCS touchscreen control system.
Tidland’s cantilevered shafts were changed from button and lug styles to the external element design and Performance Series knifeholders were added also.
He is also pleased with the coating lines’ fully automated performance. “There is no human factor of subjective intervention, so runs are more consistent through an entire shift as well as through shift changes. This consistency is critical in the manufacture of pharmaceuticals. The faster production process moves smoothly from setup to line speed.”
Another challenge addressed was tension control in the lamination process. According to Carlos Gonzales, technical supervisor, “I learned that our tension and guiding system is what it’s all about. With the great brake system that we implemented and the guiding system, we have better tension throughout the lamination systems.”
Integrating the New
In addition to the successful overhaul of its existing lines, Noven brought in a new, 30-ft. proprietary coating line.
“The main concern was the cost of floor space, which typically is $500 per square foot in pharmaceutical manufacturing,” Lima explains. “The local Maxcess representative brought in Partek Automation, an equipment OEM to oversee the integration of equipment into an entirely new process line.”
An internal team at Noven designed the concept of placing the dryer over the unwind and rewind sections to maximize the use of space. After the initial installation, Maxcess provided ongoing technical support as requested.
Jackson has been pleased with the expertise Maxcess offered Noven throughout the two-year process. For him, it’s been a valued working relationship.
“We’ve been working well with the Maxcess technician. If we want to upgrade something, we tell him this is the problem we have, and he’ll come in and assess the job. Once we purchase [the upgrade], he comes in again. We have a pretty good working relationship as far as working out any bugs. Once he knows what our problem is, he lets us know our options, and then we can choose from those options.”
For Noven, the results of upgrading and bringing in a new machine definitely have met expectations. Jackson comments, “We always had a great process. We lived with some of the problems with the old equipment, and basically we’ve enhanced what we had. We now have more control of the web, less mechanical breakdown, and faster setups.
With its coating lines upgraded, Noven Pharmaceuticals can continue to focus on its core business—the next revolutionary development in transdermal drug delivery.
As printed in PFFC Magazine, September 2006, by Nsenga Byrd Thompson, Associate Editor. Read the full article online.